URI:
   DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: OCREVUS (ocrelizumab)
       *****************************************************
       #Post#: 1787--------------------------------------------------
       HealthCanada approves Ocrevus for Canadians living with RRMS but
        apparently not PPMS so far
       By: agate Date: August 15, 2017, 7:47 pm
       ---------------------------------------------------------
       Ocrevus has been approved in Canada but for those with RRMS
       only. No mention is made of those with PPMS who were meant to be
       included among those eligible for Ocrevus.
       Speculation has it that Canadian approval for PPMS patients to
       receive Ocrevus will come along later.
       From Markets Insider (August 15, 2017):
       HealthCanada approves Ocrevus for Canadians living with RRMS
  HTML http://markets.businessinsider.com/news/stocks/Health-Canada-Approves-OCREVUS-ocrelizumab-for-Canadians-Living-with-Relapsing-Remitting-Multiple-Sclerosis-RRMS-510659
       #Post#: 1793--------------------------------------------------
       Re: HealthCanada approves Ocrevus for Canadians living with RRMS
        but apparently not PPMS so far
       By: agate Date: August 21, 2017, 9:28 pm
       ---------------------------------------------------------
       Still no explanation of the exclusion of PPMS. From Multiple
       Sclerosis News Today, August 17, 2017:
       Ocrevus Approved for RRMS Patients by Health Canada
  HTML https://multiplesclerosisnewstoday.com/2017/08/17/health-canada-approves-ocrevus-ocrelizumab-for-canadians-with-relapsing-remitting-multiple-sclerosis-rrms/?utm_source=Multiple+Sclerosis&utm_campaign=ff2814fbe1-RSS_MONDAY_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b5fb7a3dae-ff2814fbe1-71286581
       *****************************************************